MATINAS BIOPHARMA HOLDINGS I (MTNB)
US5768101058 - Common Stock
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the...
MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024
MTNB stock results show that Matinas BioPharma Hldgs met analyst estimates for earnings per share the second quarter of 2024.
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive...
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company...
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company...
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin...
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company...
MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024
MTNB stock results show that Matinas BioPharma Hldgs met analyst estimates for earnings per share the first quarter of 2024.
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner...
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company...
Matinas BioPharma Prices $10 Million Registered Direct Offering
BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a...
MTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023
Matinas BioPharma Hldgs just reported results for the fourth quarter of 2023.
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average...
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company...
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company...
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have...
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement...
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas to Meet with FDA Early...
Matinas BioPharma stock soars 80% on antifungal drug update (MTNB)
Matinas (MTNB) shares soared 80% following news that a patient with recurrent hemorrhagic cystitis was successfully treated with its antifungal drug MAT2203. Read more here.
Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
BEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on...